The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.
Women
News
November 9, 2020
News
October 9, 2020
Sex workers continue to demand decriminilisation, saying outdated lawscontribute to their abuse at the hands of police, and discrimination in society.
Resource
October 8, 2020
Introduction
Some observational data suggest that the progestogen injectable contraceptive depot medroxyprogesterone acetate (DMPA) may increase a woman’s risk of HIV acquisition but a randomized clinical trial did not find a statistically significant incre
Resource
October 5, 2020
Background:
Epidemiological data are needed to characterize the age-specific HIV burden and engagement in HIV services among young, marginalized women in sub-Saharan Africa.
Setting:
Resource
September 14, 2020
Introduction
There is a growing interest in adolescent motherhood and HIV among policymakers and programme implementers.
News
August 18, 2020
A year after the Evidence for Contraceptive Options and HIV Outcomes study, researchers say policymakers must renew their focus.
Resource
August 6, 2020
Despite the body of evidence on heterosexual men’s inequitable access to HIV prevention, testing and antiretroviral therapy (ART) [1,
Resource
July 24, 2020
Health care providers have great potential to be powerful change agents.
Resource
July 20, 2020
Introduction
Resource
July 1, 2020
The National Strategic Plan for HIV, TB and STIs (NSP) 2017-2022 Mid Term Review (MTR) was an in-depth analysis of the NSP implementation, with the aim to illustrate progress made towards reaching the NSP targets across the eight NSP goals.
